MedPath

A randomised, placebo-controlled, rising-dose crossover study to evaluate the effectiveness of modafinil in the management of fatigue in fibromyalgia - Modafinil and fibromyalgia

Phase 1
Conditions
Fibromyalgia
Registration Number
EUCTR2005-002209-22-GB
Lead Sponsor
niversity Hospitals of Leicester NHS Trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
24
Inclusion Criteria

Written Informed Consent

Widespread body pain

A positive tender point count of at least 11 out of 18 points on digital palpation

Daily fatigue of greater than 4 points on the Fatigue Scale

Fatigue for greater than 24 hours following minimal activity

Age 18 to 65 years inclusive
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

History of inflammatory disease or neoplasm

Major psychological disorders known to affect sleep as assessed by the PRIME-MD scale.

Pregnancy

Breast feeding mothers

Hypertension

Patients with a score of less than 24 out of 30 on the Mini-Mental State Exam.

Any clinically significant, uncontrolled medical or psychiatric conditions (treated or untreated)

Arrhythmia

History of left ventricular hypertrophy, cor pulmonale or mitral valve prolapse

Lactose intolerance

Known sensitivity to other constituents of modafinil tablet ie maize starch, magnesium silicate, croscarmellose sodium, Povidone K90, Talc or magnesium stearate.

Patient is taking anticonvulsants, anticoagulants, melatonin, St John’s Wort, methylphenidate, amphetamines, pemoline, zolpidem, monoamine oxidase inhibitors, barbiturates, benzodiazepines, lithium or antipsychotic drugs.

Has a significant deviation from normal in the physical examination.

Has any disorder that may interfere with drug absorption, distribution, metabolism or excretion (including gastro-intestinal surgery).

Any other sleep disorder including obstructive sleep apnoea, narcolepsy or periodic leg movement syndrome.

Previous use of Modafinil (Provigil).

Clinical history of heart, kidney or liver disease, heart attack, diseases of the CNS, alcoholism or drug dependence.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath